


PHARMACEUTICAL 2023



NightHawk Biosciences Inc. Rank 185 of 446





PHARMACEUTICAL 2023



NightHawk Biosciences Inc. Rank 185 of 446

The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 33% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 76% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	50,054
Cost of Goods Sold	6,401
Intangible Assets	11,971
Liabilities, Current	18,037
Liabilities, Non-Current	3,112
Other Assets	21,891
Other Compr. Net Income	547
Other Expenses	-2,210
Other Liabilities	10,811
Other Net Income	-1,462
Other Revenues	6,383
Property and Equipment	20,480
Research and Development	23,461
Selling, General and Administrative Expense	21,131

Output Variable	Value in 1000 USD
Assets	104,397
Liabilities	31,960
Expenses	48,783
Revenues	6,383
Stockholders Equity	72,437
Net Income	-43,862
Comprehensive Net Income	-43,589
Economic Capital Ratio	119%

